China Hot Sell Pharmaceutical Grade Tudca Tauroursodeoxycholic Acid Powder, Find details about China Tauroursodeoxycholic Powder, Tauroursodeoxycholic Acid from Hot Sell Pharmaceutical Grade Tudca Tauroursodeoxycholic Acid Powder
Product Name | Tauroursodeoxycholic Acid |
CAS No | 14605-22-2 |
Appearance | White powder |
Specification | 99% |
Certificate | ISO,SGS,HALAL,KOSHER |
Tauroursodeoxycholic Acid (TUDCA) is a liver aid introduced as a supplement by ThermoLife in their product Liver Longer. It looks like a good resource for preventing cholestasis, one of the major risks with 17 alkylated steroids.
Tauroursodeoxycholic Acid (TUDCA) is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid (UDCA). Humans are found to have trace amounts of TUDCA. However, bears contain large amounts of TUDCA in their bile.
TUDCA has diminishing apoptotic effects, helping with cardiac function, Huntington's disease, Parkinson's Disease, and stroke. Recently, TUDCA has been found to have protective effects in the eye, especially concerning retinal degenerative disorders.
1. Cooling blood and hemostasis,clearing heat and diuresis,
2. As an effective hemostat or blood coagulant that has been used to reduce or stop hemorrhage and bleeding from internal organs, particularly controlling profuse menstruation, postpartum and uterine bleeding, and blood in the urine.
3.Treatment of high blood pressure,dysentery etc.
1. Cooling blood and hemostasis,clearing heat and diuresis.
2. As an effective hemostat or blood coagulant that has been used to reduce or stop hemorrhage and bleeding from internal organs, particularly controlling profuse menstruation, postpartum and uterine bleeding, and blood in the urine.
3.Can increase the amount of bile secretion, relaxation of the bile duct sphincter produce choleretic effect, is conducive to the discharge of stones.
4.It is suitable for the treatment of cholesterol-induced stones, hyperlipidemia, bile secretory diseases, primary biliary cirrhosis, chronic hepatitis, bile reflux gastritis and prevention of acute rejection and response to liver transplantation.
5.For the treatment of gallstones, primary sclerosing cholangitis, primary biliary cirrhosis and chronic hepatitis C virus.
Item | Specification |
Assay | >98% |
Appearance | White powder |
Odor | Characteristic |
Taste | Characteristic |
Particle Size | NLT 100% Through 80 mesh |
Loss on Drying | <2.0% |
Heavy metals | ≤10ppm |
Arsenic | ≤3ppm |
Lead | ≤3ppm |
<2.0% | |
Total Plate Count | ≤1000cfu/g |
Total Yeast & Mold | ≤100cfu/g |
E.Coli | Negative |
Salmonella | Negative |